Back to Results
First PageMeta Content
Antiemetics / Abdominal pain / General practice / Syndromes / Ketones / Irritable bowel syndrome / Diarrhea / Ramosetron / 5-HT3 antagonist / Medicine / Health / Gastroenterology


Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan Tokyo, May 26, Astellas Pharma Inc. (“Astella
Add to Reading List

Document Date: 2015-05-26 01:47:13


Open Document

File Size: 73,81 KB

Share Result on Facebook
UPDATE